Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Beeton C, Pennington MW, Norton RS.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):313-21. Review.

2.

Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.

Norton RS, Pennington MW, Wulff H.

Curr Med Chem. 2004 Dec;11(23):3041-52. Review.

PMID:
15578998
3.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81. Epub 2005 Jan 21.

4.

Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG.

FASEB J. 2014 Sep;28(9):3952-64. doi: 10.1096/fj.14-251967. Epub 2014 Jun 2.

5.

Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG.

Mol Pharmacol. 2009 Apr;75(4):762-73. doi: 10.1124/mol.108.052704. Epub 2009 Jan 2.

6.

N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS.

FEBS J. 2015 Jun;282(12):2247-59. doi: 10.1111/febs.13294. Epub 2015 Apr 23.

PMID:
25864722
7.

The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS.

J Biol Chem. 2008 Jan 11;283(2):988-97. Epub 2007 Nov 5.

8.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.

Immunity. 2008 Oct 17;29(4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2.

9.

Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.

Pennington MW, Lanigan MD, Kalman K, Mahnir VM, Rauer H, McVaugh CT, Behm D, Donaldson D, Chandy KG, Kem WR, Norton RS.

Biochemistry. 1999 Nov 2;38(44):14549-58.

PMID:
10545177
10.

Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations.

Rashid MH, Kuyucak S.

J Phys Chem B. 2012 Apr 26;116(16):4812-22. doi: 10.1021/jp300639x. Epub 2012 Apr 16.

PMID:
22480371
11.

Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.

Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H.

Mol Pharmacol. 2005 Nov;68(5):1254-70. Epub 2005 Aug 11.

12.

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG.

Toxicon. 2012 Mar 15;59(4):529-46. doi: 10.1016/j.toxicon.2011.07.016. Epub 2011 Aug 12. Review.

13.

Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13942-7.

14.

Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.

Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton C.

J Biol Chem. 2014 May 2;289(18):12623-32. doi: 10.1074/jbc.M113.517037. Epub 2014 Mar 18.

15.
16.

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP.

J Pharmacol Exp Ther. 2012 Sep;342(3):642-53. doi: 10.1124/jpet.112.191890. Epub 2012 May 25.

17.

A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RS.

FEBS Lett. 2012 Nov 16;586(22):3996-4001. doi: 10.1016/j.febslet.2012.09.038. Epub 2012 Oct 9.

18.

Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.

Pennington MW, Chang SC, Chauhan S, Huq R, Tajhya RB, Chhabra S, Norton RS, Beeton C.

Mar Drugs. 2015 Jan 16;13(1):529-42. doi: 10.3390/md13010529.

19.

Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.

Chang SC, Galea CA, Leung EW, Tajhya RB, Beeton C, Pennington MW, Norton RS.

Toxicon. 2012 Oct;60(5):840-50. doi: 10.1016/j.toxicon.2012.05.017. Epub 2012 May 31.

20.

Designed peptide analogues of the potassium channel blocker ShK toxin.

Lanigan MD, Pennington MW, Lefievre Y, Rauer H, Norton RS.

Biochemistry. 2001 Dec 25;40(51):15528-37.

PMID:
11747428
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk